Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "Medical-Oncology"

88 News Found

Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer
Drug Approval | December 20, 2022

Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer

This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting


Inclusion of Yoga in the treatment of breast cancer patients is highly beneficial
News | December 13, 2022

Inclusion of Yoga in the treatment of breast cancer patients is highly beneficial

The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama


SRL Diagnostics hosts ‘International Gynecologic & Breast Cancer Symposium 2022’
News | November 23, 2022

SRL Diagnostics hosts ‘International Gynecologic & Breast Cancer Symposium 2022’

Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India


Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer
Drug Approval | September 23, 2022

Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer

One in two women with advanced ovarian cancer has an HRD-positive tumor


Tata Memorial Centre suggests low-cost intervention for breast cancer
News | September 13, 2022

Tata Memorial Centre suggests low-cost intervention for breast cancer

If implemented across the world, it has the capability to save over 100,000 lives annually


Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda  for urothelial cancer
Clinical Trials | September 13, 2022

Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda for urothelial cancer

Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab


Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA
Clinical Trials | September 12, 2022

Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA

Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022


Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer
Clinical Trials | September 10, 2022

Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer

The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients


Merck to present new data of oncology portfolio at ESMO 2022
Clinical Trials | August 30, 2022

Merck to present new data of oncology portfolio at ESMO 2022

Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)


PM to inaugurate Amrita Hospital and Homi Bhabha Cancer Hospital & Research Centre
Policy | August 23, 2022

PM to inaugurate Amrita Hospital and Homi Bhabha Cancer Hospital & Research Centre

The hospital is being constructed at an estimated cost of around Rs. 6,000 crore and will provide healthcare facilities to the people of Faridabad and the entire NCR region